FA08.05: LOSS OF SKELETAL MUSCLE MASS IN FOLLOW UP IN PALLIATIVELY STENTED ESOPHAGEAL CANCER PATIENTS PREDICTS WORSE OUTCOME

Abstract

Abstract Background Advanced esophageal cancer often causes malignant obstruction, which is widely treated with palliative insertion of a self-expandable metallic stent (SEMS). The purpose of this study was to assess, in patients who had received SEMS for palliation of malignant obstruction caused by advanced esophageal cancer, the prognostic significance of loss of muscle mass during follow up. Methods 118 patients were included. 58 (49,2%) patients had squamous cell carcinoma, 52 (44,1%) adenocarcinoma and 8 (6,7%) other histology. Two sets of abdominal CT scans of EC patients who had a stent inserted for palliation of malignant obstruction between 2005 and 2013 were analyzed (N = 118). First scan was taken at stent insertion. Median time difference between scans was 92 days. The cross-sectional total muscle area (TMA) at the level of L3 was assessed and skeletal muscle index (SMI) was calculated by dividing the TMA with the square of the patients height in cm. Follow up lasted until death for all of the 118 patients. Results Median overall survival (OS) was 188 days (IQR: 124–255 days). Median amount of weight loss during follow up was 10 kg's (IQR: 8 -16.5 kg's). Median percentual loss of SMI was 11.6% (IQR: 1.1–19.5%). Loss of more than the median amount of %SMI correlated with worse OS (187 vs. 242 days, P = 0.018), as seen in Figure 1. Conclusion In the setting of palliatively SEMS-treated esophageal cancer, the amount of skeletal muscle lost during follow up correlates with worse prognosis. Disclosure All authors have declared no conflicts of interest.